Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, raised $83 million by offering 5.5 million shares at $15, selling an additional 500,000 shares at the midpoint of the range of $14 to $16.
Milestone Pharmaceuticals plans to list on the Nasdaq under the symbol MIST. Jefferies, Cowen and Piper Jaffray acted as lead managers on the deal.
